Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment
  
Enanta announced Phase IIb results for zelicapavir in RSV among adults at high risk. (Shutterstock)

More from Clinical Trials

More from R&D